Join us in returning to NYC on June 5th to collaborate with executive leaders in exploring comprehensive methods for auditing AI models regarding bias, performance, and ethical compliance across diverse organizations. Find out how you can attend here.
Atropos Health, a healthcare technology company focused on generating personalized real-world evidence, announced today that it has raised $33 million in a Series B funding round. The round included strategic investments from healthcare giants McKesson, Merck, and Cencora Ventures, signaling strong industry interest in Atropos’ mission to bring automated, high-quality evidence to patient care decisions.
The Silicon Valley-based startup plans to use the new capital to expand its operations and double down on key initiatives such as launching in life sciences, expanding channel partnerships in value-based care and oncology, and growing its evidence network of data partners.
“We’re on a mission to bring personalized evidence for care to everybody in the world. So it’s another step in that journey,” said Atropos Health CEO and co-founder, Brigham Hyde, PhD, in an interview with VentureBeat. “Specifically, we’ll be using this to double down behind our strategic initiatives, which include continuing our launch in life sciences and building on the great traction we have there, also doubling down behind channel partners, particularly in value-based care and specialty care oncology.”
Shaping the future of healthcare delivery with AI-powered clinical evidence generation
Atropos’ core technology, Geneva OS, uses AI and automation to rapidly generate clinical-grade evidence from real-world data. Developed over nearly a dec …
Article Attribution | Read More at Article Source
Join us in returning to NYC on June 5th to collaborate with executive leaders in exploring comprehensive methods for auditing AI models regarding bias, performance, and ethical compliance across diverse organizations. Find out how you can attend here.
Atropos Health, a healthcare technology company focused on generating personalized real-world evidence, announced today that it has raised $33 million in a Series B funding round. The round included strategic investments from healthcare giants McKesson, Merck, and Cencora Ventures, signaling strong industry interest in Atropos’ mission to bring automated, high-quality evidence to patient care decisions.
The Silicon Valley-based startup plans to use the new capital to expand its operations and double down on key initiatives such as launching in life sciences, expanding channel partnerships in value-based care and oncology, and growing its evidence network of data partners.
“We’re on a mission to bring personalized evidence for care to everybody in the world. So it’s another step in that journey,” said Atropos Health CEO and co-founder, Brigham Hyde, PhD, in an interview with VentureBeat. “Specifically, we’ll be using this to double down behind our strategic initiatives, which include continuing our launch in life sciences and building on the great traction we have there, also doubling down behind channel partners, particularly in value-based care and specialty care oncology.”
Shaping the future of healthcare delivery with AI-powered clinical evidence generation
Atropos’ core technology, Geneva OS, uses AI and automation to rapidly generate clinical-grade evidence from real-world data. Developed over nearly a dec …nnDiscussion:nn” ai_name=”RocketNews AI: ” start_sentence=”Can I tell you more about this article?” text_input_placeholder=”Type ‘Yes'”]